You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Computational Infrastructure for Automated Force Field Development and Optimization
SBC: ATTMOS Inc. Topic: 400Project AbstractOur overarching goal is to provide reliable and efficient tools that can be used in structure based drug discovery (SBDD). One crucial component of SBDD is to predict the structure of a drug molecule that binds to a protein involved in a certain disease. This is usually achieved using computer tools and the process consists of two steps, namely hit identification and lead optimizat ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care
SBC: NEUROSESSMENTS LLC Topic: NIAPROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of ph ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease
SBC: Recombinant Technologies LLC Topic: NIAAbstract Alzheimer’s disease is the most common cause of dementia and fourth most common cause of death. Amyloid-beta (Aβ) plays a crucial role in initiation and progression of Alzheimer’s disease (AD). Removal of circulating Aβ would shift the equilibrium in Aβ levels between brain and blood towards blood. This shift would deplete brain amyloid levels and improve memory. Three commercial m ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Modular Virtual Reality Therapeutic for Opioid and Stimulant Use Disorders
SBC: INNATEVR LLC Topic: NIDAPROJECT SUMMARY Opioid and/or Stimulant Use Disorders (OUD/StUD) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat, with costs associated with OUD alone in the US exceeding one trillion dollars annually. Virtual Reality Cue Exposure (VRCE) employs safe and controlled repeated exposure to a variety of substance use cues and envi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Home Monitoring of Metabolic Disorders
SBC: SEQUITUR HEALTH CORP Topic: NICHDPROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
SBC: SINTX TECHNOLOGIES, INC. Topic: NIAMSPROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Engineering next generation supercharged CAR T-cells against solid tumors
SBC: Cellinfinity Bio, Inc. Topic: 102Project summary Adoptive cell therapy has revolutionized cancer treatment and has immense potential to cure a variety of cancer types. Multiple critical barriers exist for current CAR-T therapy particularly in solid tumor, including insufficient T cells trafficking to the cancer site, lack of effective cancer cell killing, severe toxicity, strong immunosuppression in the tumor microenvironment, an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New approach for immune modulation against T1D
SBC: EVOQ THERAPEUTICS, INC. Topic: 200PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is an autoimmune disease that affects 1 in 300 people by the age of 18 in the US. T1D is characterized by acute onset of hyperglycemia resulting from immune-mediated destruction of the insulin- producing β-cells in the pancreas. There is currently no cure for T1D and the disease requires constant management where the current standard of care/manageme ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy
SBC: Pure Green Pharmaceuticals Topic: 200PROJECT SUMMARY/ABSTRACT Painful diabetic peripheral neuropathy (pDPN) is a severe and debilitating nerve dysfunction prevalent in over 30 million US diabetic patients. It adversely affects patients by causing sensory pain in the lower limbs, muscular weakness, predisposition to falls, decreased quality of life, and significant patient morbidity as a result of foot ulcerations, amputations, and di ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health